BIOSCIENCE AMERICAS IS THE INTERNATIONAL DEVELOPMENT PARTNER OF THE GLOBAL INSTITUTE OF

STEM CELL THERAPY AND RESEARCH

2

GIOSTAR is the world’s leading consortium of adult stem cell research scientists. GIOSTAR maintains associations with major universities throughout the world including the University of California, Harvard University, and the Salk Institute for Biological Studies.

5

Since 2011, GIOSTAR has successfully treated more than 4,000 patients using FDA approved stem cell protocols or clinical trials at its hospital in India.

3

nGIOSTAR has been the beneficiary of more than $400 million in research grants, endowment contributions, and legislative appropriations.

nEach year more than $50 million is invested in continued research.

6

GIOSTAR uses only a patient’s own adult stem cells to cure devastating diseases and illnessess such as:

nDiabetes Type 1 and 2nLupusnMultiple SclerosisnCrohn’s DiseasenVasculitisnSclerodermanMyasthenia GravisnLou Gehrig’s DiseasenKidney Disease

As well as Sickle Cell Anemia, Lymphoma, Spinal Cord Injuries and Burns.

8

Bioscience Americas has teamed with GIOSTAR to bring the latest stem cell treatments to patients in the Western Hemisphere.

We have partnered with GIOSTAR to open wellness center clinics in South America and eventually North America and throughout the world.

7

Bioscience Americas and GIOSTAR are associated with San Vicente Hospital. San Vicente is South America’s leading hospital for organ transplants and is a major destination for transplant patients from throughout the world.

9

nThe South American market represents an $86 Billion opportunity.

nThe North American Medical Tourism market represents $55 Billion annually.

nMore than 1,200,000 U.S. patients travel outside the U.S. for medical services.

10

THE INVESTMENT OPPORTUNITY

nYour invitation to participate in a $15 million private placement capital raise for wellness center development.

nIRA and 401K Rollover qualified.

nSignificant Gains for Investors Projected.

11

YOUR REASONS TO INVEST

nBacked by more than $400 Million and 15 years of on-going research and development.

n$50 Million in annual research commitments.

nFDA approved treatments or clinical trial participation.

nParadigm shift in healthcare strategy and delivery. Patient centered focus eliminates need for surgery or drugs.

nAging population’s need for GIOSTAR/Bioscience Americas services.

n$86 Billion market in South America alone. $55 Billion U.S. medical tourism market.

n1,200,000 U.S. residents travel outside the U.S. every year for medical services.

nSuccessful delivery of adult stem cell treatments since 2011.

nMore than 4,000 patients successfully treated.

nWorld’s leading stem cell research team.

nAssociated with major medical research universities and institutions throughout the world.

nAssociated with South America‘s leading organ transplant hospital.

nPatients continue to benefit from on-going research.

nRecession Resistant.

nProprietary Technology.

nExperienced Management.

nExceptional Return on Investment projected.